Upregulation of endogenous neurotrophin levels in the brain by intranasal administration of carnosic acid

Journal of Pharmaceutical Sciences

Volumn 100, Issue 8, 2011, Pages 3139-3145

  Vaka, Siva Ram Kiran ^a   Murthy, S Narasimha ^a   Repka, Michael A ^a   Nagy, Tamas ^b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

Author keywords

BDNF; Carnosic acid; Chitosan; Cyclodextrin; Microdialysis; Microscopy; NGF; Nose to brain; Solubility

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CARNOSIC ACID; CHITOSAN; NERVE GROWTH FACTOR; NEUROTROPHIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COW; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; NONHUMAN; OLFACTORY EPITHELIUM; RAT; UPREGULATION;

EID: 79958854238     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22528     Document Type: Article

References (30)

1. Thorne RG, Frey WH. 2001. Delivery of neurotrophic factors to the central nervous system: Pharmacokinetic considerations. Clin Pharmacokinet 40:907-946.
2. Dawbarn D, Allen SJ. 2003. Neurotrophins and neurodegeneration. Neuropathol Appl Neurobiol 29:211-230.
3. Martinez HJ, Dreyfus CF, Jonakait GM, Black IB. 1985. Nerve growth factor promotes cholinergic development in brain striatal cultures. Proc Natl Acad Sci U S A 82:7777-7781.
4. Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. 2008. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 59:201-220.
5. Kordower JH, Palfi S, Chen EY, Ma SY, Sendera T, Cochran EJ, Mufson EJ, Penn R, Goetz CG, Comella CD. 1999. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46:419-424.
6. Schulte-Herbruggen O, Braun A, Rochlitzer S, Jockers-Scherubl MC, Hellweg R. 2007. Neurotrophic factors-A tool for therapeutic strategies in neurological, neuropsychiatric, and neuroimmunological diseases? Curr Med Chem 14:2318-2329.
7. Kosaka K, Yokoi T. 2003. Carnosic acid, a component of rosemary (Rosmarinus officinalis L.), promotes synthesis of nerve growth factor in T98G human glioblastoma cells. Biol Pharm Bull 26:1620-1622.
8. Satoh T, Kosaka K, Itoh K, Kobayashi A, Yamamoto M, Shimojo Y, Kitajima C, Cui J, Kamins J, Okamoto S, Izumi M, Shirasawa T, Lipton SA. 2008. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J Neurochem 104:1116-1131.
9. Park JA, Kim S, Lee SY, Kim CS, Kim do K, Kim SJ, Chun HS. 2008. Beneficial effects of carnosic acid on dieldrin-induced dopaminergic neuronal cell death. Neuroreport 19:1301-1304.
10. Krause E, Ternes W. 2000. Bioavailability of the antioxidative Rosmarinus officinalis compound carnosic acid in eggs. Eur Food Res Technol 210:161-164.
11. Oluwatuyi M, Kaatz G, Gibbons S. 2004. Antibacterial and resistance modifying activity of Rosmarinus officinalis. Phytochemistry 65:3249-3254.
12. Costa S, Utan A, Speroni E, Cervellati R, Piva G, Prandini A, Guerra MC. 2007. Carnosic acid from rosemary extracts: A potential chemoprotective agent against aflatoxin B1. An in vitro study. J Appl Toxicol 27:152-159.
13. Lee JJ, Jin YR, Lee JH, Yu JY, Han XH, Oh KW, Hong JT, Kim TJ, Yun YP. 2007. Antiplatelet activity of carnosic acid, a phenolic diterpene from Rosmarinus officinalis. Planta Med 73:121-127.
14. Yan H, Wang L, Li X, Yu C, Zhang K, Jiang Y, Wu L, Lu W, Tu P. 2009. High-performance liquid chromatography method for determination of carnosic acid in rat plasma and its application to pharmacokinetic study. Biomed Chromatogr 23:776-781.
15. Loftsson T, Masson M. 2001. Cyclodextrins in topical drug formulations: Theory and practice. Int J Pharm 225:15-30.
16. Carpenter TO, Gerloczy A, Pitha J. 1995. Safety of parenteral hydroxypropyl-β-cyclodextrin. J Pharm Sci 84:222-225.
17. Vaka SRK, Sammeta SM, Day LB, Murthy SN. 2009. Delivery of nerve growth factor to brain via intranasal administration and enhancement of brain uptake. J Pharm Sci 98:3640-3646.
18. Frey W, Liu J, Chen X, Thorne R, Fawcett J, Ala T, Rahman Y. 1997. Delivery of 125 I-NGF to the brain via the olfactory route. Drug Deliv 4:87-92.
19. Hanson LR, Frey WH. 2007. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuro AIDS. J Neuroimmune Pharmacol 2:81-86.
20. Higuchi T, Connors KA. 1965. Phase-solubility techniques. Adv Anal Chem Instr 4:117-212.
21. Loftsson T, Magnusdottir A, Masson M, Sigurjonsdottir JF. 2002. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci 91:2307-2316.
22. Loftsson T, Masson M, Sigurdsson HH. 2002. Cyclodextrins and drug permeability through semi-permeable cellophane membranes. Int J Pharm 232:35-43.
23. Schmidt MC, Simmen D, Hilbe M, Boderke P, Ditzinger G, Sandow J, Lang S, Rubas W, Merkle HP. 2000. Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium. J Pharm Sci 89:396-407.
24. Dodane V, Amin Khan M, Merwin JR. 1999. Effect of chitosan on epithelial permeability and structure. Int J Pharm 182:21-32.
25. Smith J, Wood E, Dornish M. 2004. Effect of chitosan on epithelial cell tight junctions. Pharm Res 21:43-49.
26. Furukawa Y, Furukawa S, Ikeda F, Satoyoshi E, Hayashi K. 1986. Aliphatic side chain of catecholamine potentiates the stimulatory effect of the catechol part on the synthesis of nerve growth factor. FEBS Lett 208:258-262.
27. Young AM. Intracerebral microdialysis in the study of physiology and behavior. Rev Neurosci 4:373-395.
28. Westerink BH. 1995. Brain microdialysis and its application for the study of animal behavior. Behav Brain Res 70:103-124.
29. Bradberry CW. 2000. Applications of microdialysis methodology in nonhuman primates: Practice and rationale. Crit Rev Neurobiol 14:143-163.
30. Chang Q, Savage LM, Gold PE. 2006. Microdialysis measures of functional increases in ACh release in the hippocampus with and without inclusion of acetylcholinesterase inhibitors in the perfusate. J Neurochem 97:697-706.